AU1685795A - Cis-hydroxyproline analogs for eye treatment - Google Patents

Cis-hydroxyproline analogs for eye treatment

Info

Publication number
AU1685795A
AU1685795A AU16857/95A AU1685795A AU1685795A AU 1685795 A AU1685795 A AU 1685795A AU 16857/95 A AU16857/95 A AU 16857/95A AU 1685795 A AU1685795 A AU 1685795A AU 1685795 A AU1685795 A AU 1685795A
Authority
AU
Australia
Prior art keywords
compound
haze
eye
treating
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
AU16857/95A
Other languages
English (en)
Inventor
Jonathan Javitt
Norman Javitt
Peter Mcdonnell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU1685795A publication Critical patent/AU1685795A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
AU16857/95A 1994-01-21 1995-01-23 Cis-hydroxyproline analogs for eye treatment Withdrawn AU1685795A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18411894A 1994-01-21 1994-01-21
US184118 1994-01-21
PCT/US1995/000809 WO1995019764A1 (fr) 1994-01-21 1995-01-23 Analogues de la cis-hydroxyproline destines au traitement ophtalmologique

Publications (1)

Publication Number Publication Date
AU1685795A true AU1685795A (en) 1995-08-08

Family

ID=22675616

Family Applications (1)

Application Number Title Priority Date Filing Date
AU16857/95A Withdrawn AU1685795A (en) 1994-01-21 1995-01-23 Cis-hydroxyproline analogs for eye treatment

Country Status (5)

Country Link
EP (1) EP0740549A1 (fr)
JP (1) JPH09510962A (fr)
AU (1) AU1685795A (fr)
CA (1) CA2181788A1 (fr)
WO (1) WO1995019764A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4397197A (en) * 1996-09-28 1998-04-17 Kissei Pharmaceutical Co. Ltd. Subepithelial turbidity inhibitor
IT1305306B1 (it) * 1999-03-17 2001-05-04 Farmigea Spa Uso della pirenoxina per la protezione dei tessuti corneali ininterventi di fotocheratectomia.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444787A (en) * 1981-07-06 1984-04-24 Board Of Regents, University Of Texas Ophthalmic topical use of collagen cross-linking inhibitors
US4428939A (en) * 1981-10-16 1984-01-31 Prockop Darwin J Collagen inhibiting compositions and processes for manufacturing and using same
US5021404A (en) * 1988-04-20 1991-06-04 The Children's Medical Center Corporation Angiostatic collagen modulators

Also Published As

Publication number Publication date
CA2181788A1 (fr) 1995-07-27
EP0740549A1 (fr) 1996-11-06
JPH09510962A (ja) 1997-11-04
WO1995019764A1 (fr) 1995-07-27

Similar Documents

Publication Publication Date Title
Campos et al. Clinical follow-up of phototherapeutic keratectomy for treatment of corneal opacities
Vigo et al. Scraping and mitomycin C to treat haze and regression after photorefractive keratectomy for myopia
Serdarevic et al. Excimer laser therapy for experimental Candida keratitis
Rapuano Excimer laser phototherapeutic keratectomy: long-term results and practical considerations
Ditzen et al. Photorefractive keratectomy to treat low, medium, and high myopia: a multicenter study
Thomann et al. Phototherapeutic keratectomy for bullous keratopathy.
Förster et al. Therapeutic use of the 193-nm excimer laser in corneal pathologies
Nassaralla et al. Prophylactic mitomycin C to inhibit corneal haze after photorefractive keratectomy for residual myopia following radial keratotomy
Im et al. Combined ethylenediaminetetraacetic acid chelation, phototherapeutic keratectomy and amniotic membrane transplantation for treatment of band keratopathy
Starr et al. Excimer laser phototherapeutic keratectomy
Cameron et al. Excimer laser phototherapeutic keratectomy for shield ulcers and corneal plaques in vernal keratoconjunctivitis
de Benito-Llopis et al. Effect of mitomycin-C on the corneal endothelium during excimer laser surface ablation
Suarez et al. LASIK for correction of hyperopia and hyperopia with astigmatism
Porges et al. Phototherapeutic keratectomy with mitomycin C for corneal haze following photorefractive keratectomy for myopia
EP1187611B1 (fr) Compositions ophtalmiques a base d'histamine et leurs utilisations
de Benito-Llopis et al. Comparison between LASEK with mitomycin C and LASIK for the correction of myopia of-7.00 to-13.75 D
Bilgihan et al. Topical vitamin E and hydrocortisone acetate treatment after photorefractive keratectomy
US6117907A (en) Topical treatment of ocular pain after corneal surgery
AU1685795A (en) Cis-hydroxyproline analogs for eye treatment
Tuunanen et al. Excimer laser phototherapeutic keratectomy for corneal diseases: a follow-up study
US6180673B1 (en) Corneal subepithelial opacity (haze) inhibitor
Bergman et al. The role of fibroblast inhibitors on corneal healing following photorefractive keratectomy with 193-nanometer excimer laser in rabbits
Autrata et al. Phototherapeutic keratectomy in children: 5-year results
US5296514A (en) Corneal treatment agents
US5098896A (en) Corneal treatment agents